Yao Zhu, MD, PhD, presented “Epidemiology & Genomics of Prostate Cancer in Asian Men” for the Grand Rounds in Urology audience in June, 2020.
How to cite: Zhu, Yao. “Epidemiology & Genomics of Prostate Cancer in Asian Men” June, 2020. Accessed Nov 2025. https://grandroundsinurology.com/epidemiology-genomics-of-prostate-cancer-in-asian-men/
Epidemiology & Genomics of Prostate Cancer in Asian Men – Summary:
In conversation with Peter K.F. Chiu, MD, PhD, FRCSEd, Honorary Clinical Assistant Professor and Associate Consultant in the Division of Urology at the Chinese University of Hong Kong, Yao Zhu, MD, PhD, attending urologist at Fudan University Shanghai Cancer Center and Associate Professor in Oncology at Shanghai Medical College, discusses the increasing number of deaths from prostate cancer in East Asia, emphasizing the need to develop Asian-specific genetic risk models. Dr. Zhu notes that while data on non-Western populations has been relatively limited to this point, there appear to be numerous differences in prostate cancer-related mutations between East Asian men and Western men, including lower rates of TMPRSS2-ERG fusion and PTEN deletion, and increased prevalence of FOXA1, SPOP, CHD1, and BRCA2. He also observes that there are pharmacogenomic implications to differences in testosterone metabolism-related genes between East Asian and Western men.
For more information on genetic & genomic testing for prostate cancer, visit our Next Generation Learning Center.
ABOUT THE AUTHOR
Yao Zhu, MD, PhD, is the Chief Physician, a Professor, the PhD Supervisor, and the Deputy Director of the Department of Urology at Fudan University Shanghai Cancer Center in Shanghai, China. Dr. Zhu specializes in the early diagnosis and radical treatment of prostate cancer, as well as the precision diagnosis and treatment of refractory cases. His primary research focus is on the precision diagnosis and treatment of prostate cancer resistance.
Dr. Zhu received his MD from Fudan University. He then completed an internship and residency in the Department of Urology at Fudan University Shanghai Cancer Center.
Dr. Zhu has authored numerous key academic papers as the corresponding author inEuropean Urology, Med, Journal of the NCCN, Clinical Cancer Research,andEJNMMI. He was also invited to write a review forNature Reviews Urologyon precision subtyping and treatment strategies for prostate cancer in Asia (2021) and on the biological mechanisms and clinical management of prostate cancer liver metastasis (2024). Dr. Zhu has led five projects funded by the National Natural Science Foundation and has received numerous accolades, including the Shanghai Youth Science and Technology Star Program, Top Ten Young Physicians of Fudan University, the Shanghai Municipal Health Commission Youth May Fourth Medal, and the “Top Ten Outstanding Young Doctors” award at Fudan University.
